<article title='Ciprofloxacin'><paragraph><template><target>Redirect</target><arg>Cipro</arg><arg>the Rome Metro station</arg><arg>Cipro (Rome Metro)</arg></template><template><target>Use dmy dates</target><arg name="date">August 2012</arg></template><template><target>drugbox</target><arg name="Watchedfields"><space/>changed
</arg><arg name="verifiedrevid"><space/>443526033
</arg><arg name="drug_name"><space/>Ciprofloxacin<space/><small>({{abbr|INN|International Nonproprietary Name}})</small>
</arg><arg name="IUPAC_name"><space/>1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid
</arg><arg name="image"><space/>Ciprofloxacin.svg
</arg><arg name="width"><space/>200
</arg><arg name="image2"><space/>Ciprofloxacin-zwitterion-from-xtal-3D-balls.png

<space/></arg><arg name="tradename"><space/>Ciloxan, Cipro, Neofloxin
</arg><arg name="Drugs.com"><space/>{{drugs.com|monograph|ciprofloxacin-hydrochloride}}
</arg><arg name="MedlinePlus"><space/>a688016
</arg><arg name="licence_US"><space/>Ciprofloxacin
</arg><arg name="pregnancy_AU"><space/>B3
</arg><arg name="pregnancy_US"><space/>C
</arg><arg name="legal_AU"><space/>S4
</arg><arg name="legal_UK"><space/>POM
</arg><arg name="legal_US"><space/>Rx-only
</arg><arg name="routes_of_administration"><space/>[[Route of administration#Enteral|Oral]], [[intravenous therapy|intravenous]], [[topical]] ([[ear drop]]s, [[eye drop]]s)

<space/></arg><arg name="bioavailability"><space/>69%<ref>{{cite journal |author1-last</arg><arg name="metabolism"><space/>Hepatic, including [[CYP1A2]]
</arg><arg name="elimination_half-life"><space/>4 hours
</arg><arg name="excretion"><space/>Kidneys

<space/></arg><arg name="CAS_number_Ref"><space/>{{cascite|correct|??}}
</arg><arg name="CAS_number"><space/>85721-33-1
</arg><arg name="ATC_prefix"><space/>J01
</arg><arg name="ATC_suffix"><space/>MA02
</arg><arg name="ATC_supplemental"><space/>{{ATC|S01|AE03}} {{ATC|S02|AA15}} {{ATC|S03|AA07}}
</arg><arg name="ChEBI_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEBI"><space/>100241
</arg><arg name="PubChem"><space/>2764
</arg><arg name="DrugBank_Ref"><space/>{{drugbankcite|correct|drugbank}}
</arg><arg name="DrugBank"><space/>DB00537
</arg><arg name="ChemSpiderID_Ref"><space/>{{chemspidercite|correct|chemspider}}
</arg><arg name="ChemSpiderID"><space/>2662
</arg><arg name="UNII_Ref"><space/>{{fdacite|correct|FDA}}
</arg><arg name="UNII"><space/>5E8K9I0O4U
</arg><arg name="KEGG_Ref"><space/>{{keggcite|correct|kegg}}
</arg><arg name="KEGG"><space/>D00186
</arg><arg name="ChEMBL_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEMBL"><space/>8
</arg><arg name="NIAID_ChemDB"><space/>001992

<space/></arg><arg name="C">17<space/></arg><arg name="H">18<space/></arg><arg name="F">1<space/></arg><arg name="N">3<space/></arg><arg name="O">3
</arg><arg name="molecular_weight"><space/>331.346 g/mol
</arg><arg name="smiles"><space/>c1c2c(cc(c1F)N3CCNCC3)n(cc(c2</arg><arg name="InChI"><space/>1/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
</arg><arg name="StdInChI_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChI"><space/>1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
</arg><arg name="StdInChIKey_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChIKey"><space/>MYSWGUAQZAJSOK-UHFFFAOYSA-N
</arg></template></paragraph><preblock><preline><bold>Ciprofloxacin</bold><space/>is an<space/><link><target>antibiotic</target></link><space/>used to treat a number of<space/><link><target>bacterial infections</target></link>.<extension extension_name='ref' name="AHFS2015"><template><target>cite web</target><arg name="title">Ciprofloxacin Hydrochloride
</arg><arg name="url">http://www.drugs.com/monograph/ciprofloxacin-hydrochloride.html</arg><arg name="publisher">The American Society of Health-System Pharmacists</arg><arg name="accessdate">Aug 23, 2015</arg></template></extension><space/>This includes bone and<space/><link><target>joint infection</target><trail>s</trail></link>, intra abdominal infections, certain type of<space/><link><target>infectious diarrhea</target></link>,<space/><link><target>respiratory tract infection</target><trail>s</trail></link>, skin infections,<space/><link><target>typhoid fever</target></link>, and<space/><link><target>urinary tract infection</target><trail>s</trail></link>, among others.<extension extension_name='ref' name="AHFS2015"></extension><space/>For some infections it is used in addition to other antibiotics.<extension extension_name='ref' name="AHFS2015"></extension><space/>It can be taken by mouth or used intravenously.<extension extension_name='ref' name="AHFS2015"></extension></preline></preblock><preblock><preline>Common side effects include nausea, vomiting, diarrhea, and rash.<extension extension_name='ref' name="AHFS2015"></extension><space/>Ciprofloxacin increases the risk of<space/><link><target>tendon rupture</target></link><space/>and worsening muscle weakness in people with the neurological disorder<space/><link><target>myasthenia gravis</target></link>.<extension extension_name='ref' name="AHFS2015"></extension><space/>Rates of side effects appear to be higher than some groups of antibiotics such as<space/><link><target>cephalosporin</target><trail>s</trail></link><space/>but lower than others such as<space/><link><target>clindamycin</target></link>.<extension extension_name='ref' name="He2013"><template><target>cite journal</target><arg name="author">Heidelbaugh JJ, Holmstrom H<space/></arg><arg name="title">The perils of prescribing fluoroquinolones<space/></arg><arg name="journal">J Fam Pract<space/></arg><arg name="volume">62<space/></arg><arg name="issue">4<space/></arg><arg name="pages">191–7<space/></arg><arg name="date">April 2013<space/></arg><arg name="pmid">23570031<space/></arg><arg name="doi"><space/></arg><arg name="url"></arg><arg name="last2">Holmstrom<space/></arg></template></extension><space/>Studies in other animals raise concerns regarding use in<space/><link><target>pregnancy</target></link>.<extension extension_name='ref' name="AG2015"></extension><space/>No problems were identified; however, in the children of a small number of women who took the medication.<extension extension_name='ref' name="AG2015"><template><target>cite web</target><arg name="title">Prescribing medicines in pregnancy database</arg><arg name="url">http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw</arg><arg name="work">Australian Government</arg><arg name="date">23 Aug 2015</arg></template></extension><space/>It appears to be safe during<space/><link><target>breastfeeding</target></link>.<extension extension_name='ref' name="AHFS2015"></extension><space/>It is a second-generation<space/><link><target>fluoroquinolone</target></link><space/>with a<space/><link><target>Broad-spectrum antibiotic</target><part>broad spectrum of activity</part></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Ball P<space/></arg><arg name="title">Quinolone generations: natural history or natural selection?<space/></arg><arg name="journal">J. Antimicrob. Chemother.<space/></arg><arg name="volume">46 Suppl T1<space/></arg><arg name="issue"><space/></arg><arg name="pages">17–24<space/></arg><arg name="date">July 2000<space/></arg><arg name="pmid">10997595<space/></arg><arg name="doi"><space/>10.1093/oxfordjournals.jac.a020889</arg><arg name="url"></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Oliphant CM, Green GM<space/></arg><arg name="title">Quinolones: a comprehensive review<space/></arg><arg name="journal">Am Fam Physician<space/></arg><arg name="volume">65<space/></arg><arg name="issue">3<space/></arg><arg name="pages">455–64<space/></arg><arg name="date">February 2002<space/></arg><arg name="pmid">11858629<space/></arg><arg name="doi"><space/></arg><arg name="url"></arg><arg name="last2">Green<space/></arg></template></extension></preline></preblock><preblock><preline>Ciprofloxacin was introduced in 1987.<extension extension_name='ref'><template><target>cite book</target><arg name="title">Oxford Handbook of Infectious Diseases and Microbiology</arg><arg name="date">2009</arg><arg name="publisher">OUP Oxford</arg><arg name="isbn">9780191039621</arg><arg name="page">56</arg><arg name="url">https://books.google.ca/books?id</arg></template></extension><space/>It is on the<space/><link><target>World Health Organization's List of Essential Medicines</target></link>, the most important medications needed in a basic<space/><link><target>health system</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf<space/></arg><arg name="title">19th WHO Model List of Essential Medicines (April 2015)<space/></arg><arg name="date">April 2015<space/></arg><arg name="accessdate">May 10, 2015<space/></arg><arg name="publisher">WHO<space/></arg></template></extension><space/>It is available as a generic medication and not very expensive.<extension extension_name='ref' name="AHFS2015"></extension><extension extension_name='ref' name="Ric2014"><template><target>cite book</target><arg name="last1">Hamilton</arg><arg name="first1">Richard J.</arg><arg name="title">Tarascon pharmacopoeia</arg><arg name="date">2014</arg><arg name="publisher">Jones & Bartlett Publishers</arg><arg name="isbn">9781284056716</arg><arg name="page">85</arg><arg name="edition">15</arg><arg name="url">https://books.google.ca/books?id</arg></template></extension><space/>Wholesale it costs between 0.03 and 0.13 USD a dose.<extension extension_name='ref' name="ERC2015"><template><target>cite web</target><arg name="title">Ciprofloxacin</arg><arg name="url">http://erc.msh.org/dmpguide/resultsdetail.cfm?language</arg><arg name="website">International Drug Price Indicator Guide</arg><arg name="accessdate">24 August 2015</arg></template></extension><space/>In the United States it is sold for about 0.40 USD per dose.<extension extension_name='ref' name="AHFS2015"></extension></preline></preblock><heading level='2'>Medical uses</heading><paragraph>Ciprofloxacin is used to treat a wide variety of infections, including infections of bones and joints,<space/><link><target>endocarditis</target></link>,<space/><link><target>gastroenteritis</target></link>,<space/><link><target>malignant otitis externa</target></link>,<space/><link><target>respiratory tract infections</target></link>,<space/><link><target>cellulitis</target></link>,<space/><link><target>urinary tract infections</target></link>,<space/><link><target>prostatitis</target></link>,<space/><link><target>anthrax</target></link>, and<space/><link><target>chancroid</target></link>.<extension extension_name='ref' name="AHFS"><template><target>cite web</target><arg name="title">Ciprofloxacin-Hydrochloride</arg><arg name="url">http://www.drugs.com/monograph/ciprofloxacin-hydrochloride.html</arg><arg name="work">The American Society of Health-System Pharmacists</arg><arg name="accessdate">3 April 2011</arg></template></extension></paragraph><paragraph>Ciprofloxacin only treats bacterial infections; it does not treat viral infections such as the common cold. For certain uses including acute sinusitis, lower respiratory tract infections and uncomplicated gonorrhea, ciprofloxacin is not considered a first-line agent.</paragraph><paragraph>Ciprofloxacin occupies an important role in treatment guidelines issued by major medical societies for the treatment of serious infections, especially those likely to be caused by Gram-negative bacteria, including<space/><italics><link><target>Pseudomonas aeruginosa</target></link></italics>. For example, ciprofloxacin in combination with<space/><link><target>metronidazole</target></link><space/>is one of several first-line antibiotic regimens recommended by the Infectious Diseases Society of America for the treatment of community-acquired abdominal infections in adults.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://cid.oxfordjournals.org/content/50/2/133.full<space/></arg><arg name="title">Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>It also features prominently in treatment guidelines for acute pyelonephritis, complicated or hospital-acquired urinary tract infection, acute or chronic prostatitis,<extension extension_name='ref' name="www.uroweb.org"><template><target>cite web</target><arg name="url">http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf<space/></arg><arg name="title">www.uroweb.org<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>certain types of endocarditis,<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://circ.ahajournals.org/content/111/23/e394.full<space/></arg><arg name="title">Infective Endocarditis<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>certain skin infections,<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://cid.oxfordjournals.org/content/41/10/1373.full<space/></arg><arg name="title">Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>and prosthetic joint infections.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://cid.oxfordjournals.org/content/early/2012/11/29/cid.cis803.abstract.html?papetoc<space/></arg><arg name="title">Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension></paragraph><paragraph>In other cases, treatment guidelines are more restrictive, recommending in most cases that older, narrower-spectrum drugs be used as first-line therapy for less severe infections to minimize fluoroquinolone-resistance development. For example, the Infectious Diseases Society of America recommends the use of ciprofloxacin and other fluoroquinolones in urinary tract infections be reserved to cases of proven or expected resistance to narrower-spectrum drugs such as<space/><link><target>nitrofurantoin</target></link><space/>or<space/><link><target>trimethoprim/sulfamethoxazole</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://cid.oxfordjournals.org/content/52/5/e103.full?ijkey</arg><arg name="title">International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>The European Association of Urology recommends ciprofloxacin as an alternative regimen for the treatment of uncomplicated urinary tract infections, but cautions that the potential for adverse events have to be considered.<extension extension_name='ref' name="www.uroweb.org"></extension></paragraph><paragraph>Although approved by regulatory authorities for the treatment of respiratory infections, ciprofloxacin is not recommended for respiratory infections by most treatment guidelines due in part to its modest activity against the common respiratory pathogen<space/><italics><link><target>Streptococcus pneumoniae</target></link></italics>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://pharmacy.oregonstate.edu/drug_policy/pages/dur_board/reviews/articles/dur_review_2002_05_02_fluroquinolone.pdf<space/></arg><arg name="title">pharmacy.oregonstate.edu<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><extension extension_name='ref' name="cfaeocb"><template><target>cite journal</target><arg name="author">Zuger A<space/></arg><arg name="date">3 November 1998<space/></arg><arg name="title">Ciprofloxacin for Acute Exacerbations of Chronic Bronchitis<space/></arg><arg name="journal">Journal Watch (General)<space/></arg><arg name="url">http://general-medicine.jwatch.org/cgi/content/citation/1998/1103/4<space/></arg><arg name="quote">Because of its unpredictable activity against the pneumococcus, ciprofloxacin is not usually considered a first-line treatment for respiratory infections...<space/></arg><arg name="volume">1998<space/></arg><arg name="issue">1103<space/></arg><arg name="page">4<space/></arg></template></extension><extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Vardakas<space/></arg><arg name="first1"><space/>KZ<space/></arg><arg name="last2"><space/>Siempos<space/></arg><arg name="first2"><space/>II<space/></arg><arg name="last3"><space/>Grammatikos<space/></arg><arg name="first3"><space/>A<space/></arg><arg name="last4"><space/>Athanassa<space/></arg><arg name="first4"><space/>Z<space/></arg><arg name="last5"><space/>Korbila<space/></arg><arg name="first5"><space/>IP<space/></arg><arg name="last6"><space/>Falagas<space/></arg><arg name="first6"><space/>ME<space/></arg><arg name="title"><space/>Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials<space/></arg><arg name="journal"><space/>CMAJ<space/></arg><arg name="volume"><space/>179<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1269–77<space/></arg><arg name="date">December 2008<space/></arg><arg name="doi"><space/>10.1503/cmaj.080358<space/></arg><arg name="pmid"><space/>19047608<space/></arg><arg name="pmc"><space/>2585120<space/></arg></template></extension><extension extension_name='ref' name="pmid8019264"><template><target>cite journal</target><arg name="last1"><space/>Donaldson<space/></arg><arg name="first1"><space/>PM<space/></arg><arg name="last2"><space/>Pallett<space/></arg><arg name="first2"><space/>AP<space/></arg><arg name="last3"><space/>Carroll<space/></arg><arg name="first3"><space/>MP<space/></arg><arg name="title"><space/>Ciprofloxacin in general practice<space/></arg><arg name="journal"><space/>BMJ (Clinical Research Ed.)<space/></arg><arg name="volume"><space/>308<space/></arg><arg name="issue"><space/>6941<space/></arg><arg name="page"><space/>1437<space/></arg><arg name="date">May 1994<space/></arg><arg name="pmid"><space/>8019264<space/></arg><arg name="pmc"><space/>2540361<space/></arg><arg name="issn"><space/>0959-8138<space/></arg><arg name="doi">10.1136/bmj.308.6941.1437</arg></template></extension><space/>&quot;Respiratory quinolones&quot; such as<space/><link><target>levofloxacin</target></link>, having greater activity against this pathogen, are recommended as first line agents for the treatment of community-acquired pneumonia in patients with important co-morbidities and in patients requiring hospitalization (Infectious Diseases Society of America 2007). Similarly, ciprofloxacin is not recommended as a first-line treatment for<space/><link><target>acute sinusitis</target></link>.<extension extension_name='ref' name="Karageorgopoulos-2008"><template><target>Cite journal</target><arg name="last1"><space/>Karageorgopoulos<space/></arg><arg name="first1"><space/>DE.<space/></arg><arg name="last2"><space/>Giannopoulou<space/></arg><arg name="first2"><space/>KP.<space/></arg><arg name="last3"><space/>Grammatikos<space/></arg><arg name="first3"><space/>AP.<space/></arg><arg name="last4"><space/>Dimopoulos<space/></arg><arg name="first4"><space/>G.<space/></arg><arg name="last5"><space/>Falagas<space/></arg><arg name="first5"><space/>ME.<space/></arg><arg name="title"><space/>Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials<space/></arg><arg name="journal"><space/>CMAJ<space/></arg><arg name="volume"><space/>178<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>845–54<space/></arg><arg name="date">March 2008<space/></arg><arg name="doi"><space/>10.1503/cmaj.071157<space/></arg><arg name="pmid"><space/>18362380<space/></arg><arg name="pmc"><space/>2267830</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Chow AW, Benninger MS, Brook I<space/></arg><arg name="title">IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults<space/></arg><arg name="journal">Clin. Infect. Dis.<space/></arg><arg name="volume">54<space/></arg><arg name="issue">8<space/></arg><arg name="pages">e72–e112<space/></arg><arg name="date">April 2012<space/></arg><arg name="pmid">22438350<space/></arg><arg name="doi">10.1093/cid/cir1043<space/></arg><arg name="url"></arg><arg name="author2">and others<space/></arg><arg name="displayauthors">1<space/></arg></template></extension></paragraph><paragraph>Ciprofloxacin is approved for the treatment of gonorrhea in many countries, but this recommendation is widely regarded as obsolete due to resistance development.<extension extension_name='ref'>(World Health Organization (WHO) Western Pacific Region Gonococcal Antimicrobial Susceptibility Programme (GASP) Report- 2000. Commun Dis Intell 2001; 25:274-277)</extension><extension extension_name='ref'><template><target>cite web</target><arg name="author">Department of Health and Human Services<space/></arg><arg name="authorlink">Department of Health and Human Services<space/></arg><arg name="author2">Centers for Disease Control and Prevention<space/></arg><arg name="title">Gonococcal Isolate Surveillance Project (GISP) Annual Report - 2003<space/></arg><arg name="url">http://www.cdc.gov/STD/gisp2003/GISP2003.pdf<space/></arg><arg name="publisher">Center for Disease Controlo<space/></arg><arg name="location">USA<space/></arg><arg name="format">PDF<space/></arg><arg name="date">November 2004<space/></arg><arg name="accessdate">31 August 2009</arg><arg name="authorlink2">Centers for Disease Control and Prevention<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Hugh Young<space/></arg><arg name="date">22 July 2003<space/></arg><arg name="title">Ciprofloxacin resistant gonorrhoea: the situation in Scotland and implications for therapy<space/></arg><arg name="journal">SCIEH Weekly Report - SCOTTISH CENTRE FOR INFECTION AND ENVIRONMENTAL HEALTH<space/></arg><arg name="volume">37<space/></arg><arg name="publisher">National Health Service<space/></arg><arg name="location">Scotland<space/></arg><arg name="issn">1357-4493<space/></arg><arg name="doi"><space/></arg><arg name="url">http://www.documents.hps.scot.nhs.uk/ewr/pdf2003/0329.pdf<space/></arg><arg name="format">PDF<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="date">13 April 2007<space/></arg><arg name="title">Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections.</arg><arg name="journal">Morbidity and Mortality Weekly Report<space/></arg><arg name="volume">56<space/></arg><arg name="issue">14<space/></arg><arg name="pages">332–336<space/></arg><arg name="publisher">Center for Disease Control<space/></arg><arg name="location">USA<space/></arg><arg name="url"><space/></arg><arg name="format">PDF<space/></arg><arg name="pmid">17431378<space/></arg><arg name="author">Centers for Disease Control and Prevention (CDC)<space/></arg></template></extension></paragraph><heading level='3'>Pregnancy</heading><paragraph>The U.S. FDA categorizes ciprofloxacin in<space/><link><target>pregnancy category</target></link><space/>C.<extension extension_name='ref'><link type='external' href='http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s074,020780s032lbl.pdf'>FDA-approved drug label</link></extension><space/>This category includes drugs for which no adequate and well-controlled studies in human pregnancy exist, and for which animal studies have suggested the potential for harm to the fetus, but potential benefits may warrant use of the drug in pregnant womendespite potential risks. An expert review of published data on experiences with ciprofloxacin use during pregnancy by the Teratogen Information System concluded therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (quantity and quality of data=fair), but the data are insufficient to state no risk exists.<extension extension_name='ref'><template><target>cite book</target><arg name="last1"><space/>Friedman<space/></arg><arg name="first1"><space/>J.<space/></arg><arg name="last2"><space/>Polifka<space/></arg><arg name="first2"><space/>J.<space/></arg><arg name="title"><space/>Teratogenic effects of drugs: a resource for clinicians (TERIS)<space/></arg><arg name="publisher"><space/>Johns Hopkins University Press<space/></arg><arg name="year"><space/>2000<space/></arg><arg name="location"><space/>Baltimore, Maryland<space/></arg><arg name="pages"><space/>149–195</arg></template></extension></paragraph><paragraph>Two small post-marketing epidemiology studies of mostly short-term, first-trimester exposure found that fluoroquinolones did not increase risk of major malformations, spontaneous abortions, premature birth, or low birth weight.<extension extension_name='ref' name="pmid9624471"><template><target>cite journal</target><arg name="author">Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE</arg><arg name="title">Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study<space/></arg><arg name="journal">Antimicrob Agents Chemother<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="volume"><space/>42<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1336–9<space/></arg><arg name="pmid">9624471<space/></arg><arg name="doi"><space/></arg><arg name="pmc">105599<space/></arg><arg name="author2">and others<space/></arg><arg name="displayauthors">1<space/></arg></template></extension><extension extension_name='ref' name="pmid8902438"><template><target>cite journal</target><arg name="author">Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E</arg><arg name="title">Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS)<space/></arg><arg name="journal">Eur J Obstet Gynecol Reprod Biol<space/></arg><arg name="year"><space/>1996<space/></arg><arg name="volume"><space/>69<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>83–9<space/></arg><arg name="pmid">8902438<space/></arg><arg name="doi"><space/>10.1016/0301-2115(95)02524-3</arg><arg name="pmc"><space/></arg><arg name="url">http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom</arg><arg name="author2">and others<space/></arg><arg name="displayauthors">1<space/></arg></template></extension><space/>The label notes, however, that these studies are insufficient to reliably evaluate the definitive safety or risk of less common defects by ciprofloxacin in pregnant women and their developing fetuses.</paragraph><heading level='3'>Breastfeeding</heading><paragraph>The fluoroquinolones have also been reported as being present in the mother's milk and are passed on to the nursing child.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Shin HC, Kim JC, Chung MK<space/></arg><arg name="title">Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats<space/></arg><arg name="journal">Comp. Biochem. Physiol. C Toxicol. Pharmacol.<space/></arg><arg name="volume">136<space/></arg><arg name="issue">1<space/></arg><arg name="pages">95–102<space/></arg><arg name="date">September 2003<space/></arg><arg name="pmid">14522602<space/></arg><arg name="doi"><space/>10.1016/j.cca.2003.08.004</arg><arg name="url"><space/></arg><arg name="first1">HC<space/></arg><arg name="last2">Kim<space/></arg><arg name="first2">JC<space/></arg><arg name="last3">Chung<space/></arg><arg name="first3">MK<space/></arg><arg name="last4">Jung<space/></arg><arg name="first4">YH<space/></arg><arg name="last5">Kim<space/></arg><arg name="first5">JS<space/></arg><arg name="last6">Lee<space/></arg><arg name="first6">MK<space/></arg><arg name="last7">Amidon<space/></arg><arg name="first7">GL<space/></arg><arg name="issn">1532-0456</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H<space/></arg><arg name="title">Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women<space/></arg><arg name="journal">Antimicrob. Agents Chemother.<space/></arg><arg name="volume">37<space/></arg><arg name="issue">2<space/></arg><arg name="pages">293–6<space/></arg><arg name="date">February 1993<space/></arg><arg name="pmid">8452360<space/></arg><arg name="pmc">187655<space/></arg><arg name="doi"><space/>10.1128/AAC.37.2.293</arg><arg name="url">http://aac.asm.org/cgi/pmidlookup?view</arg><arg name="first1">M<space/></arg><arg name="last2">Weidekamm<space/></arg><arg name="first2">E<space/></arg><arg name="last3">Sagiv<space/></arg><arg name="first3">R<space/></arg><arg name="last4">Portmann<space/></arg><arg name="first4">R<space/></arg><arg name="last5">Zakut<space/></arg><arg name="first5">H<space/></arg><arg name="issn">0066-4804</arg></template></extension><space/>The U.S. FDA recommends that because of the risk of serious adverse reactions (including articular damage) in infants nursing from mothers taking ciprofloxacin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</paragraph><heading level='3'>Children</heading><paragraph>Oral and intravenous ciprofloxacin are approved by the FDA for use in children for only two indications due to the risk of permanent injury to the musculoskeletal system:</paragraph><preblock><preline></preline></preblock><paragraph>1) Inhalational<space/><link><target>anthrax</target></link><space/>(postexposure)<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/20780S08ltr.pdf<space/></arg><arg name="title">Cipro Labeling Revision Letter 08/30/2000 Supplement 008 New or Modified Indication<space/></arg><arg name="author">Dianne Murphy<space/></arg><arg name="publisher">U.S. Food and Drug Administration<space/></arg><arg name="date"><space/>30 August 2000<space/></arg></template></extension></paragraph><paragraph>2) Complicated urinary tract infections and<space/><link><target>pyelonephritis</target></link><space/>due to<space/><italics>Escherichia coli</italics>,<extension extension_name='ref' name="cipro2004"><template><target>cite web</target><arg name="author">Renata Albrecht<space/></arg><arg name="title">Cipro Labeling Revision Letter 03/25/2004 Supplement 049 Patient Population Altered<space/></arg><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19537s049,19857s031,19847s027,20780s013ltr.pdf<space/></arg><arg name="publisher">[[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA)<space/></arg><arg name="date">25 March 2004<space/></arg><arg name="accessdate">7 September 2009</arg></template></extension><space/>but never as first-line agents. Current recommendations by the American Academy of Pediatrics note the systemic use of ciprofloxacin in children should be restricted to infections caused by multidrug-resistant pathogens or when no safe or effective alternatives are available.<extension extension_name='ref' name="c2009"><template><target>cite web</target><arg name="author">Lexi-Comp<space/></arg><arg name="title">Ciprofloxacin<space/></arg><arg name="url">http://www.merck.com/mmpe/lexicomp/ciprofloxacin.html<space/></arg><arg name="publisher">Merk<space/></arg><arg name="date">February 2009<space/></arg><arg name="accessdate">4 September 2009</arg></template></extension></paragraph><heading level='3'>Spectrum of activity</heading><paragraph>Its spectrum of activity includes most strains of bacterial pathogens responsible for respiratory, urinary tract, gastrointestinal, and abdominal infections, including<space/><link><target>Gram-negative</target></link><space/>(<italics><link><target>Escherichia coli</target></link></italics>,<space/><italics><link><target>Haemophilus influenzae</target></link></italics>,<space/><italics><link><target>Klebsiella pneumoniae</target></link></italics>,<space/><italics><link><target>Legionella pneumophila</target></link></italics>,<space/><italics><link><target>Moraxella catarrhalis</target></link></italics>,<space/><italics><link><target>Proteus mirabilis</target></link></italics>, and<space/><italics><link><target>Pseudomonas aeruginosa</target></link></italics>), and<space/><link><target>Gram-positive</target></link><space/>(methicillin-sensitive, but not methicillin-resistant<space/><italics><link><target>Staphylococcus aureus</target></link></italics>,<space/><italics><link><target>Streptococcus pneumoniae</target></link></italics>,<space/><italics><link><target>Staphylococcus epidermidis</target></link></italics>,<space/><italics><link><target>Enterococcus faecalis</target></link></italics>, and<space/><italics><link><target>Streptococcus pyogenes</target></link></italics>) bacterial pathogens.</paragraph><heading level='3'>Bacterial resistance</heading><paragraph><template><target>See also</target><arg>Antibiotic abuse</arg><arg>Antibiotic resistance</arg></template>As a result of its widespread use to treat minor infections readily treatable with older, narrower spectrum antibiotics, many bacteria have developed resistance to this drug in recent years, leaving it significantly less effective than it would have been otherwise.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.cdc.gov/ncidod/eid/vol5no3/pdf/vatopoulos.pdf<space/></arg><arg name="title">Bacterial Resistance to Ciprofloxacin in Greece: Results from the National Electronic Surveillance System<space/></arg><arg name="author">A.C. Vatopoulos<space/></arg><arg name="author2">V. Kalapothaki<space/></arg><arg name="format">PDF<space/></arg><arg name="year">1997<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.health.state.mn.us/news/pressrel/2009/bacterial022609.html<space/></arg><arg name="title">Bacterial resistance prompts concern among health officials<space/></arg><arg name="first"><space/></arg><arg name="last"><space/></arg><arg name="authorlink"><space/></arg><arg name="publisher"><space/></arg><arg name="location"><space/></arg><arg name="date">26 February 2009<space/></arg><arg name="deadurl">yes<space/></arg><arg name="archiveurl">https://web.archive.org/20090305232555/http://www.health.state.mn.us:80/news/pressrel/2009/bacterial022609.html<space/></arg><arg name="archivedate">5 March 2009<space/></arg></template></extension></paragraph><paragraph><link><target>Antibiotic resistance</target><part>Resistance</part></link><space/>to ciprofloxacin and other fluoroquinolones may evolve rapidly, even during a course of treatment. Numerous<space/><link><target>pathogen</target><trail>s</trail></link>, including<space/><link><target>enterococci</target></link>,<space/><italics><link><target>Streptococcus pyogenes</target></link></italics><space/>and<space/><italics><link><target>Klebsiella pneumoniae</target></link></italics><space/>(quinolone-resistant) now exhibit resistance.<extension extension_name='ref'>M Jacobs, Worldwide Overview of Antimicrobial Resistance. International Symposium on Antimicrobial Agents and Resistance 2005.</extension><space/>Widespread veterinary usage of the fluoroquinolones, particularly in Europe, has been implicated.<extension extension_name='ref'><template><target>cite press release</target><arg name="title">Update On Extra-Label Use Of Fluoroquinolones<space/></arg><arg name="url">http://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm127657.htm<space/></arg><arg name="publisher"><space/>[[Center for Veterinary Medicine]] (CVM)<space/></arg><arg name="date">16 July 1996<space/></arg><arg name="accessdate">12 August 2009</arg></template></extension><space/>Meanwhile, some<space/><italics><link><target>Burkholderia cepacia</target></link></italics>,<space/><italics><link><target>Clostridium innocuum</target></link></italics><space/>and<space/><italics><link><target>Enterococcus faecium</target></link></italics><space/>strains have developed resistance to ciprofloxacin to varying degrees.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Ciprofloxacin spectrum of bacterial susceptibility and Resistance</arg><arg name="url">http://www.toku-e.com/Upload/Products/PDS/20120618005735.pdf<space/></arg><arg name="accessdate">4 May 2012</arg></template></extension></paragraph><paragraph>Fluoroquinolones had become the class of antibiotics most commonly prescribed to adults in 2002.<extension extension_name='ref' name="pmid15745724"><template><target>cite journal</target><arg name="author">Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS<space/></arg><arg name="title">Fluoroquinolone prescribing in the United States: 1995 to 2002<space/></arg><arg name="journal">Am. J. Med.<space/></arg><arg name="volume">118<space/></arg><arg name="issue">3<space/></arg><arg name="pages">259–68<space/></arg><arg name="date">March 2005<space/></arg><arg name="pmid">15745724<space/></arg><arg name="doi">10.1016/j.amjmed.2004.09.015<space/></arg><arg name="last2">Huang<space/></arg><arg name="last3">Steinman<space/></arg><arg name="last4">Gonzales<space/></arg><arg name="last5">Stafford<space/></arg></template></extension><space/>Nearly half (42%) of those prescriptions in the U.S. were for conditions not approved by the FDA, such as acute bronchitis, otitis media, and acute upper respiratory tract infection, according to a study supported in part by the Agency for Healthcare Research and Quality.<extension extension_name='ref' name="pmid15745724"></extension><extension extension_name='ref'>K08 HS14563 and HS11313<template><target>full</target><arg name="date">May 2013</arg></template></extension><space/>Additionally, they were commonly prescribed for medical conditions that were not even bacterial to begin with, such as viral infections, or those to which no proven benefit existed.</paragraph><heading level='2'>Adverse effects</heading><paragraph>Rates of side effects appear to be higher than with some groups of antibiotics such as<space/><link><target>cephalosporin</target><trail>s</trail></link><space/>but lower than with others such as<space/><link><target>clindamycin</target></link>.<extension extension_name='ref' name="He2013"></extension></paragraph><paragraph>Compared to other antibiotics some studies find a higher rate of side affects<extension extension_name='ref' name="Br2013"><template><target>cite journal</target><arg name="author">Brown KA, Khanafer N, Daneman N, Fisman DN<space/></arg><arg name="title">Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection<space/></arg><arg name="journal">Antimicrob. Agents Chemother.<space/></arg><arg name="volume">57<space/></arg><arg name="issue">5<space/></arg><arg name="pages">2326–32<space/></arg><arg name="date">May 2013<space/></arg><arg name="pmid">23478961<space/></arg><arg name="pmc">3632900<space/></arg><arg name="doi">10.1128/AAC.02176-12<space/></arg><arg name="url"></arg><arg name="last2">Khanafer<space/></arg><arg name="last3">Daneman<space/></arg><arg name="last4">Fisman<space/></arg></template></extension><extension extension_name='ref' name="Fal2006"><template><target>cite journal</target><arg name="author">Falagas ME, Matthaiou DK, Vardakas KZ<space/></arg><arg name="title">Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: a meta-analysis of randomized controlled trials<space/></arg><arg name="journal">Mayo Clin. Proc.<space/></arg><arg name="volume">81<space/></arg><arg name="issue">12<space/></arg><arg name="pages">1553–66<space/></arg><arg name="date">December 2006<space/></arg><arg name="pmid">17165634<space/></arg><arg name="doi"><space/>10.4065/81.12.1553</arg><arg name="url"></arg><arg name="last2">Matthaiou<space/></arg><arg name="last3">Vardakas<space/></arg></template></extension><space/>while others find no difference.<extension extension_name='ref' name="Kn2012"><template><target>cite journal</target><arg name="author">Knottnerus BJ, Grigoryan L, Geerlings SE<space/></arg><arg name="title">Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials<space/></arg><arg name="journal">Fam Pract<space/></arg><arg name="volume">29<space/></arg><arg name="issue">6<space/></arg><arg name="pages">659–70<space/></arg><arg name="date">December 2012<space/></arg><arg name="pmid">22516128<space/></arg><arg name="doi">10.1093/fampra/cms029<space/></arg><arg name="url"></arg><arg name="author2">and others<space/></arg><arg name="displayauthors">1<space/></arg></template></extension></paragraph><paragraph>In pre-approval clinical trials of ciprofloxacin most of the adverse events reported were described as mild or moderate in severity, abated soon after the drug was discontinued, and required no treatment.<extension extension_name='ref'><link type='external' href='http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s074,020780s032lbl.pdf'>FDA-approved package insert</link></extension><space/>Ciprofloxacin was discontinued because of an adverse event in 1% of orally treated patients. The most frequently reported drug-related events, from clinical trials of all formulations, all dosages, all drug-therapy durations, and for all indications of ciprofloxacin therapy, were nausea (2.5%), diarrhea (1.6%), abnormal liver function tests (1.3%), vomiting (1%), and rash (1%). Other adverse events occurred at rates of &lt;1%.</paragraph><paragraph>The<space/><link><target>Boxed warning</target><part>black box warning</part></link><space/>on the U.S. FDA-approved ciprofloxacin label warns of an increased risk of<space/><link><target>tendinitis</target></link><space/>and tendon rupture, especially in patients who are older than 60 years, patients who also use corticosteroids, and patients with kidney, lung, or heart transplants. Tendon rupture can occur during therapy or even months after discontinuation of the drug.<extension extension_name='ref'><template><target>cite journal</target><arg name="pmid">10970974<space/></arg><arg name="date">September 2000<space/></arg><arg name="last1">Saint<space/></arg><arg name="first1">F<space/></arg><arg name="last2">Gueguen<space/></arg><arg name="last3">Biserte<space/></arg><arg name="last4">Fontaine<space/></arg><arg name="last5">Mazeman<space/></arg><arg name="title">Rupture of the patellar ligament one month after treatment with fluoroquinolone<space/></arg><arg name="volume">86<space/></arg><arg name="issue">5<space/></arg><arg name="pages">495–7<space/></arg><arg name="issn">0035-1040<space/></arg><arg name="journal">Revue de chirurgie orthopedique et reparatrice de l'appareil moteur<space/></arg></template></extension><space/>A case control study<extension extension_name='ref'><template><target>cite journal</target><arg name="author">van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH<space/></arg><arg name="title">Fluoroquinolones and risk of Achilles tendon disorders: case-control study<space/></arg><arg name="journal">BMJ<space/></arg><arg name="volume">324<space/></arg><arg name="issue">7349<space/></arg><arg name="pages">1306–7<space/></arg><arg name="date">June 2002<space/></arg><arg name="pmid">12039823<space/></arg><arg name="pmc">113766<space/></arg><arg name="doi"><space/>10.1136/bmj.324.7349.1306</arg><arg name="url"></arg><arg name="last2">Sturkenboom<space/></arg><arg name="last3">Herings<space/></arg><arg name="last4">Leufkens<space/></arg><arg name="last5">Stricker<space/></arg></template></extension><space/>performed using a UK medical care database found that fluoroquinolone use was associated with a 1.9-fold increase in tendon problems. The relative risk increased to 3.2 in those over 60 years of age and to 6.2 in those over the age of 60 who were also taking corticosteroids. Among the 46,766 quinolone users in the study, 38 (0.1%) cases of Achilles tendon rupture were identified. A study performed using an Italian healthcare database reached qualitatively similar conclusions.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Corrao G, Zambon A, Bertù L<space/></arg><arg name="title">Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study<space/></arg><arg name="journal">Drug Saf<space/></arg><arg name="volume">29<space/></arg><arg name="issue">10<space/></arg><arg name="pages">889–96<space/></arg><arg name="year">2006<space/></arg><arg name="pmid">16970512<space/></arg><arg name="doi"><space/>10.2165/00002018-200629100-00006</arg><arg name="url"></arg><arg name="author2">and others<space/></arg><arg name="displayauthors">1<space/></arg></template></extension></paragraph><paragraph>The other black box warning is that ciprofloxacin should not be used in patients with<space/><link><target>myasthenia gravis</target></link><space/>due to possible exacerbation of muscle weakness which may lead to breathing problems resulting in death or ventilator support. Fluoroquinolones are known to block neuromuscular transmission. &lt;ref name=&quot;www.accessdata.fda.gov&quot;/<extension extension_name='ref'>http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s075,020780s033lbl.pdf</extension></paragraph><paragraph><italics><link><target>Clostridium difficile (bacteria)</target><part>Clostridium difficile</part></link></italics>-associated diarrhea is a serious adverse effect of ciprofloxacin and other fluoroquinolones; it is unclear whether the risk is higher than with other broad-spectrum antibiotics.<extension extension_name='ref' name="pmid18067688"><template><target>cite journal</target><arg name="author">Deshpande A, Pant C, Jain A, Fraser TG, Rolston DD</arg><arg name="title">Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence<space/></arg><arg name="journal">Curr Med Res Opin<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="volume"><space/>24<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>329–33<space/></arg><arg name="pmid">18067688<space/></arg><arg name="doi">10.1185/030079908X253735<space/></arg><arg name="pmc"><space/></arg><arg name="url">http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom</arg><arg name="last2">Pant<space/></arg><arg name="last3">Jain<space/></arg><arg name="last4">Fraser<space/></arg><arg name="last5">Rolston<space/></arg></template></extension></paragraph><paragraph>The 2013 FDA label warns of nervous system effects. Ciprofloxacin, like other fluoroquinolones, is known to trigger seizures or lower the seizure threshold, and may cause other central nervous system side effects. Headache, dizziness, and insomnia have been reported as occurring fairly commonly in postapproval review articles, along with a much lower incidence of serious CNS side effects such as tremors, psychosis, anxiety, hallucinations, paranoia, and suicide attempts, especially at higher doses.<extension extension_name='ref' name="He2013"></extension><space/>Like other fluoroquinolones, it is also known to cause peripheral neuropathy that may be irreversible, such as weakness, burning pain, tingling, or numbness.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm<space/></arg><arg name="title">FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection<space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension></paragraph><paragraph>A wide range of rare but potentially fatal side effects spontaneously reported to the U.S. FDA or the subject of case reports published in medical journals includes, but is not limited to,<space/><link><target>toxic epidermal necrolysis</target></link>,<space/><link><target>Stevens-Johnson syndrome</target></link>, heart arrhythmias (<italics><link><target>torsades de pointes</target></link></italics><space/>or<space/><link><target>Long QT syndrome</target><part>QT prolongation</part></link>), allergic pneumonitis, bone marrow suppression, hepatitis or liver failure,<extension extension_name='ref' name="pmid24352180"><template><target>cite journal</target><arg name="author">Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, Laplante KL</arg><arg name="title">Risk of hepatotoxicity associated with fluoroquinolones: A national case-control safety study<space/></arg><arg name="journal">Am J Health Syst Pharm<space/></arg><arg name="year"><space/>2014<space/></arg><arg name="volume"><space/>71<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>37–43<space/></arg><arg name="pmid">24352180<space/></arg><arg name="doi">10.2146/ajhp130165<space/></arg><arg name="pmc"><space/></arg><arg name="url">http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom</arg><arg name="last2">Larrat<space/></arg><arg name="last3">Morrill<space/></arg><arg name="last4">Caffrey<space/></arg><arg name="last5">Quilliam<space/></arg><arg name="last6">Laplante<space/></arg></template></extension><space/>and phototoxicity/photosensitivity. The drug should be discontinued if a rash, jaundice, or other sign of hypersentitivity occur.<extension extension_name='ref' name="http"><template><target>cite web</target><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019537s082,020780s040lbl.pdf<space/></arg><arg name="title">Cipro Immediate Release Tablets Prescribing Information<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension></paragraph><paragraph>Children and the elderly are at a much greater risk of experiencing adverse reactions.<extension extension_name='ref' name="autogenerated1403"><template><target>cite journal</target><arg name="pmid">17559736<space/></arg><arg name="date">June 2007<space/></arg><arg name="last1">Iannini<space/></arg><arg name="first1">PB<space/></arg><arg name="title">The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.<space/></arg><arg name="volume">23<space/></arg><arg name="issue">6<space/></arg><arg name="pages">1403–13<space/></arg><arg name="issn">0300-7995<space/></arg><arg name="doi">10.1185/030079907X188099<space/></arg><arg name="journal">Current medical research and opinion<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="pmid">15942881<space/></arg><arg name="date">July 2005<space/></arg><arg name="last1">Owens Rc<space/></arg><arg name="first1">Jr<space/></arg><arg name="last2">Ambrose<space/></arg><arg name="first2">P. G.<space/></arg><arg name="title">Antimicrobial safety: focus on fluoroquinolones<space/></arg><arg name="volume">41 Suppl 2<space/></arg><arg name="pages">S144–57<space/></arg><arg name="issn">1058-4838<space/></arg><arg name="doi">10.1086/428055<space/></arg><arg name="journal">Clinical Infectious Diseases<space/></arg></template></extension></paragraph><heading level='3'>Contraindications</heading><paragraph>Two contraindications are found within the 2013 package insert:<extension extension_name='ref' name="accessdata.fda.gov"><template><target>cite web</target><arg name="title">Cipro Labeling Revision 02/25/2011 Supplement 075<space/></arg><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s075,020780s033lbl.pdf<space/></arg><arg name="publisher">[[Food and Drug Administration (United States)|US Food and Drug Administration]] (FDA)<space/></arg><arg name="date">25 February 2011<space/></arg><arg name="accessdate">1 April 2011<space/></arg></template></extension></paragraph><list type='bullet'><listitem>Concomitant administration with<space/><link><target>tizanidine</target></link><space/>is contraindicated.</listitem></list><list type='bullet'><listitem>Administration to anyone with a history of hypersensitivity to any member of the quinolone class of antimicrobial agents, including ciprofloxacin, or any of the product components is contraindicated.</listitem></list><paragraph>Ciprofloxacin is also considered to be contraindicated within the pediatric population (except for the indications outlined above), in<space/><link><target>pregnancy</target></link>, to nursing mothers, and in patients with<space/><link><target>epilepsy</target></link><space/>or other seizure disorders.</paragraph><heading level='3'>Genotoxicity and carcinogenicity</heading><paragraph>Ciprofloxacin is active in six of eight<space/><italics>in vitro</italics><space/>assays used as rapid screens for the detection of genotoxic effects, but is not active in<space/><italics>in vivo</italics><space/>assays of genotoxicity.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s074,020780s032lbl.pdf<space/></arg><arg name="title">CIPRO® (ciprofloxacin hydrochloride) TABLETS<br>CIPRO® (ciprofloxacin*) ORAL SUSPENSION<space/></arg><arg name="format">PDF<space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>Long-term carcinogenicity studies in rats and mice resulted in no carcinogenic or tumorigenic effects due to ciprofloxacin at daily oral dose levels up to 250 and 750&amp;nbsp;mg/kg to rats and mice, respectively (about 1.7 and 2.5 times the highest recommended therapeutic dose based upon mg/m<xhtml:sup>2</xhtml:sup>). Results from photo co-carcinogenicity testing indicate ciprofloxacin does not reduce the time to appearance of UV-induced skin tumors as compared to vehicle control.</paragraph><heading level='3'>Interactions</heading><paragraph>Ciprofloxacin interacts with certain foods and several other drugs leading to undesirable increases or decreases in the serum levels or distribution of one or both drugs.</paragraph><paragraph>Ciprofloxacin should not be taken with antacids containing magnesium or aluminum, highly buffered drugs (<link><target>sevelamer</target></link>,<space/><link><target>lanthanum carbonate</target></link>,<space/><link><target>sucralfate</target></link>,<space/><link><target>didanosine</target></link>), or with supplements containing calcium, iron, or zinc. It should be taken two hours before or six hours after these products. Magnesium or aluminum antacids turn ciprofloxacin into insoluble salts that are not readily absorbed by the intestinal tract, reducing peak serum concentrations by 90% or more, leading to therapeutic failure. Additionally, it should not be taken with dairy products or calcium-fortified juices alone, as peak serum concentration and the area under the serum concentration-time curve can be reduced up to 40%. However, ciprofloxacin may be taken with dairy products or calcium-fortified juices as part of a meal.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Rodvold KA, Piscitelli SC<space/></arg><arg name="title">New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety<space/></arg><arg name="journal">Clin. Infect. Dis.<space/></arg><arg name="volume">17 Suppl 1<space/></arg><arg name="issue"><space/></arg><arg name="pages">S192–9<space/></arg><arg name="date">August 1993<space/></arg><arg name="pmid">8399914<space/></arg><arg name="doi"><space/>10.1093/clinids/17.supplement_1.s192</arg><arg name="url"></arg><arg name="last2">Piscitelli<space/></arg></template></extension><extension extension_name='ref' name="FDA 81532304, R.1"></extension><extension extension_name='ref' name="Bolhuis MS, Panday PN, Pranger AD, Kosterink JG, Alffenaar JW 2011 865913"><template><target>cite journal</target><arg name="author">Bolhuis MS, Panday PN, Pranger AD, Kosterink JG, Alffenaar JW<space/></arg><arg name="title">Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams<space/></arg><arg name="journal">Pharmaceutics<space/></arg><arg name="volume">3<space/></arg><arg name="issue">4<space/></arg><arg name="pages">865–913<space/></arg><arg name="year">2011<space/></arg><arg name="pmid">24309312<space/></arg><arg name="pmc">3857062<space/></arg><arg name="doi">10.3390/pharmaceutics3040865<space/></arg><arg name="url"></arg><arg name="last2">Panday<space/></arg><arg name="last3">Pranger<space/></arg><arg name="last4">Kosterink<space/></arg><arg name="last5">Alffenaar<space/></arg></template></extension></paragraph><paragraph>Ciprofloxacin inhibits the drug-metabolizing enzyme<space/><link><target>CYP1A2</target></link><space/>and thereby can reduce the clearance of drugs metabolized by that enzyme. CYP1A2 substrates that exhibit increased serum levels in ciprofloxacin-treated patients include<space/><link><target>tizanidine</target></link>,<space/><link><target>theophylline</target></link>,<space/><link><target>caffeine</target></link>,<space/><link><target>methylxanthines</target></link>,<space/><link><target>clozapine</target></link>,<space/><link><target>olanzapine</target></link>, and<space/><link><target>ropinirole</target></link>. Co-administration of ciprofloxacin with the CYP1A2 substrate tizanidine (Zanaflex) is contraindicated due to a 583% increase in the peak serum concentrations of tizanidine when administered with ciprofloxacin as compared to administration of tizanidine alone. Use of ciprofloxacin is cautioned in patients on theophylline due to its narrow therapeutic index. The authors of one review recommended that patients being treated with ciprofloxacin reduce their caffeine intake. Evidence for significant interactions with several other CYP1A2 substrates such as<space/><link><target>cyclosporine</target></link><space/>is equivocal or conflicting.<extension extension_name='ref' name="Bolhuis MS, Panday PN, Pranger AD, Kosterink JG, Alffenaar JW 2011 865913"></extension><extension extension_name='ref' name="ctcos"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Janknegt R<space/></arg><arg name="title">Drug interactions with quinolones<space/></arg><arg name="journal">[[J. Antimicrob. Chemother.]]<space/></arg><arg name="volume">26 Suppl D<space/></arg><arg name="issue"><space/></arg><arg name="pages">7–29<space/></arg><arg name="date">November 1990<space/></arg><arg name="pmid">2286594<space/></arg><arg name="doi"><space/>10.1093/jac/26.suppl_D.7</arg><arg name="url"><space/></arg><arg name="first1">R<space/></arg><arg name="issn">0305-7453</arg></template></extension></paragraph><paragraph>The<space/><link><target>Committee on Safety of Medicines</target></link><space/>and the FDA warn that<space/><link><target>central nervous system</target></link><space/>adverse effects, including seizure risk, may be increased when<space/><link><target>NSAID</target><trail>s</trail></link><space/>are combined with quinolones.<extension extension_name='ref' name="ctcos"><template><target>cite web</target><arg name="title">Cipro Labeling Revision 10/03/2008 Supplement 068<space/></arg><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019537s68,19847s42,19857s49,20780s26,21473s24lbl.pdf<space/></arg><arg name="publisher">US Food and Drug Administration<space/></arg><arg name="date"><space/>3 October 2008<space/></arg><arg name="accessdate">31 August 2009</arg></template></extension><extension extension_name='ref'><template><target>cite book</target><arg name="title">[[British National Formulary]] (BNF 57)<space/></arg><arg name="author">Royal Pharmaceutical Society of Great Britain<space/></arg><arg name="authorlink">Royal Pharmaceutical Society of Great Britain<space/></arg><arg name="publisher">BMJ Group and RPS Publishing<space/></arg><arg name="chapter">5 Infections<space/></arg><arg name="year">2009<space/></arg><arg name="isbn">978-0-85369-845-6<space/></arg></template></extension><space/>The mechanism for this interaction may involve a<space/><link><target>synergistic</target></link><space/>increased antagonism of GABA neurotransmission.<extension extension_name='ref' name="pmid11172695"><template><target>cite journal</target><arg name="author">De Sarro A, De Sarro G<space/></arg><arg name="title">Adverse reactions to fluoroquinolones. an overview on mechanistic aspects<space/></arg><arg name="journal">Curr. Med. Chem.<space/></arg><arg name="volume">8<space/></arg><arg name="issue">4<space/></arg><arg name="pages">371–84<space/></arg><arg name="date">March 2001<space/></arg><arg name="pmid">11172695<space/></arg><arg name="doi"><space/>10.2174/0929867013373435</arg><arg name="url"></arg><arg name="last2">De Sarro<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Brouwers JR<space/></arg><arg name="title">Drug interactions with quinolone antibacterials<space/></arg><arg name="journal">Drug Saf<space/></arg><arg name="volume">7<space/></arg><arg name="issue">4<space/></arg><arg name="pages">268–81<space/></arg><arg name="date">July 1992<space/></arg><arg name="pmid">1524699<space/></arg><arg name="doi">10.2165/00002018-199207040-00003<space/></arg><arg name="first1">JR<space/></arg><arg name="issn">0114-5916<space/></arg></template></extension></paragraph><paragraph>Altered serum levels of the antiepileptic drugs<space/><link><target>phenytoin</target></link><space/>and<space/><link><target>carbamazepine</target></link><space/>(increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.<extension extension_name='ref' name="ctcos"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Shahzadi A, Javed I, Aslam B</arg><arg name="title">Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers</arg><arg name="journal">Pak J Pharm Sci<space/></arg><arg name="volume">24<space/></arg><arg name="issue">1<space/></arg><arg name="pages">63–68</arg><arg name="date">January 2011</arg><arg name="pmid">21190921</arg><arg name="url">http://www.pjps.pk/CD-PJPS-24-1-11/Paper-12.pdf<space/></arg><arg name="author2">and others</arg><arg name="displayauthors">1</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/carn-bcei_v8n1-eng.pdf<space/></arg><arg name="title">Risk of seizures from concomitant use of ciprofloxacin and phenytoin in patients with epilepsy<space/></arg><arg name="accessdate">30 January 2009<space/></arg><arg name="author">Carol Langlois<space/></arg><arg name="author2">Pascale Springuel<space/></arg><arg name="date">January 1998<space/></arg><arg name="format">PDF<space/></arg><arg name="publisher">Canadian Adverse Drug Reaction Newsletter<space/></arg><arg name="location">Canada</arg></template></extension></paragraph><heading level='3'>Overdose</heading><paragraph>Overdose of ciprofloxacin may result in reversible renal toxicity. Treatment of overdose includes emptying of the stomach by induced vomiting or<space/><link><target>gastric lavage</target></link>, as well as administration of antacids containing magnesium, aluminum, or calcium to reduce drug absorption. Renal function and urinary pH should be monitored. Important support includes adequate hydration and urine acidification if necessary to prevent crystalluria.<space/><link><target>Hemodialysis</target></link><space/>or<space/><link><target>peritoneal dialysis</target></link><space/>can only remove less than 10% of ciprofloxacin.<extension extension_name='ref' name="FDA 81532304, R.1"><template><target>cite web</target><arg name="title">Cipro Labeling Revision 04/06/2009 Supplement 073<space/></arg><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019537s073,020780s030lbl.pdf<space/></arg><arg name="publisher">US Food and Drug Administration<space/></arg><arg name="date">6 April 2009<space/></arg><arg name="accessdate">8 September 2009</arg></template></extension><space/>Ciprofloxacin may be quantified in plasma or serum to monitor for drug accumulation in patients with hepatic dysfunction or to confirm a diagnosis of poisoning in acute overdose victims.<extension extension_name='ref'>R. Baselt,<space/><italics>Disposition of Toxic Drugs and Chemicals in Man</italics>, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 313-315. ISBN 978-0-9626523-7-0.</extension></paragraph><heading level='2'>Mechanism of action</heading><paragraph>Ciprofloxacin is a<space/><link><target>broad-spectrum antibiotic</target></link><space/>active against both<space/><link><target>Gram-positive</target></link><space/>and<space/><link><target>Gram-negative</target></link><space/>bacteria. It functions by inhibiting<space/><link><target>DNA gyrase</target></link>, a type II<space/><link><target>topoisomerase</target></link>, and topoisomerase IV,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Drlica K, Zhao X<space/></arg><arg name="title">DNA gyrase, topoisomerase IV, and the 4-quinolones<space/></arg><arg name="journal">Microbiol Mol Biol Rev.<space/></arg><arg name="volume">61<space/></arg><arg name="issue">3<space/></arg><arg name="pages">377–92<space/></arg><arg name="pmid">9293187<space/></arg><arg name="pmc">232616<space/></arg><arg name="url">http://mmbr.asm.org/cgi/pmidlookup?view</arg><arg name="date"><space/>1 September 1997<space/></arg><arg name="first1">K<space/></arg><arg name="last2">Zhao<space/></arg><arg name="first2">X<space/></arg><arg name="issn">1092-2172</arg></template></extension><space/>enzymes<space/><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Pommier Y., Leo E., Zhang H., Marchand C.<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="title"><space/>DNA topoisomerases and their poisoning by anticancer and antibacterial drugs<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Chem. Biol<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/>5</arg><arg name="pages"><space/>421–433<space/></arg><arg name="doi">10.1016/j.chembiol.2010.04.012</arg><arg name="pmid"><space/>20534341<space/></arg><arg name="last2"><space/>Leo<space/></arg><arg name="last3"><space/>Zhang<space/></arg><arg name="last4"><space/>Marchand<space/></arg></template></extension><space/>necessary to separate bacterial DNA, thereby inhibiting cell division.</paragraph><heading level='2'>Pharmacokinetics</heading><paragraph>Ciprofloxacin for systemic administration is available as immediate-release tablets, extended-release tablets, an oral suspension, and as a solution for intravenous administration. When administered over one hour as an intravenous infusion,<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019847s054lbl.pdf<space/></arg><arg name="title">Cipro IV Prescribing Information<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>ciprofloxacin rapidly distributes into the tissues, with levels in some tissues exceeding those in the serum. Penetration into the central nervous system is relatively modest, with cerebrospinal fluid levels normally less than 10% of peak serum concentrations. The serum half-life of ciprofloxacin is about 46 hours, with 50-70% of an administered dose being excreted in the urine as unmetabolized drug. An additional 10% is excreted in urine as metabolites. Urinary excretion is virtually complete 24 hours after administration. Dose adjustment is required in the elderly and in those with renal impairment.</paragraph><paragraph>Ciprofloxacin is weakly bound to serum proteins (20-40%), but is an inhibitor of the drug-metabolizing enzyme cytochrome P450 1A2, which leads to the potential for clinically important drug interactions with drugs metabolized by that enzyme.<template><target>medical citation needed</target><arg name="date">August 2015</arg></template></paragraph><paragraph>Ciprofloxacin is about 70% orally available when administered orally, so a slightly higher dose is needed to achieve the same exposure when switching from IV to oral administration. A 750-mg immediate-release oral tablet given every 12 hours produces about the same area under the serum concentration curve (AUC) and peak serum concentration (C<xhtml:sub>max</xhtml:sub>) as a 400-mg dose given every 8 hours IV.<extension extension_name='ref' name="http"></extension><space/>The extended release oral tablets<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21554_ciproXR_lbl.pdf<space/></arg><arg name="title">Cipro XR Prescribing Information<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>allow once-daily administration by releasing the drug more slowly in the gastrointestinal tract. These tablets contain 35% of the administered dose in an immediate-release form and 65% in a slow-release matrix. Maximum serum concentrations are achieved between 1 and 4 hours after administration. Compared to the 250- and 500-mg immediate-release tablets, the 500-mg and 1000-mg XR tablets provide higher C<xhtml:sub>max</xhtml:sub>, but the 24hour AUCs are equivalent.</paragraph><paragraph>Ciprofloxacin immediate-release tablets contain ciprofloxacin as the hydrochloride salt, and the XR tablets contain a mixture of the hydrochloride salt as the free base.</paragraph><heading level='2'>Chemical properties</heading><paragraph>Ciprofloxacin is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its empirical formula is C<xhtml:sub>17</xhtml:sub>H<xhtml:sub>18</xhtml:sub>FN<xhtml:sub>3</xhtml:sub>O<xhtml:sub>3</xhtml:sub><space/>and its molecular weight is 331.4 g/mol. It is a faintly yellowish to light yellow crystalline substance.<extension extension_name='ref' name="FDA 81532304, R.1"></extension></paragraph><paragraph>Ciprofloxacin hydrochloride (<link><target>United States Pharmacopeia</target><part>USP</part></link>) is the monohydrochloride monohydrate salt of ciprofloxacin. It is a faintly yellowish to light yellow crystalline substance with a molecular weight of 385.8 g/mol. Its empirical formula is C<xhtml:sub>17</xhtml:sub>H<xhtml:sub>18</xhtml:sub>FN<xhtml:sub>3</xhtml:sub>O<xhtml:sub>3</xhtml:sub>HClH<xhtml:sub>2</xhtml:sub>O.<extension extension_name='ref' name="FDA 81532304, R.1"></extension></paragraph><heading level='2'>Usage</heading><paragraph>Ciprofloxacin is the most widely used of the second-generation quinolone.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Goossens H, Ferech M, Coenen S, Stephens P<space/></arg><arg name="title">Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries<space/></arg><arg name="journal">Clin. Infect. Dis.<space/></arg><arg name="volume">44<space/></arg><arg name="issue">8<space/></arg><arg name="pages">1091–5<space/></arg><arg name="date">April 2007<space/></arg><arg name="pmid">17366456<space/></arg><arg name="doi">10.1086/512810<space/></arg><arg name="url"></arg><arg name="last2">Ferech<space/></arg><arg name="last3">Coenen<space/></arg><arg name="last4">Stephens<space/></arg><arg name="author5">European Surveillance of Antimicrobial Consumption Project Group<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.bccdc.ca/NR/rdonlyres/BC629780-7E03-4153-B67B-5CFD4F521DAC/0/Full2010AntibioticConsumptionReport_aug2012.pdf<space/></arg><arg name="title">British Columbia Annual Summary of Antibiotics Utilization 2010</arg><arg name="format"><space/>PDF</arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>In 2010, over 20 million prescriptions were written, making it the 35th-most commonly prescribed drug, and the 5th-most commonly prescribed antibacterial, in the U.S.<extension extension_name='ref'><template><target>Cite web</target><arg name="last"><space/></arg><arg name="first"><space/></arg><arg name="title"><space/>http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard/drugtopics/252011/727243/article.pdf<space/></arg><arg name="url"><space/>http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard/drugtopics/252011/727243/article.pdf<space/></arg><arg name="publisher"><space/></arg><arg name="accessdate"><space/>2 November 2012<space/></arg><arg name="archivedate"><space/>15 December 2012</arg><arg name="archiveurl">https://web.archive.org/web/20121215070930/http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727243/article.pdf</arg></template></extension></paragraph><heading level='2'>History</heading><paragraph><link><target>Image:Cipro 250 mg.JPG</target><part>thumb</part><part>Ciprofloxacin 250-mg tablets from Ukraine</part></link>The first members of the quinolone antibacterial class were relatively low-potency drugs such as<space/><link><target>nalidixic acid</target></link>, used mainly in the treatment of urinary tract infections owing to their renal excretion and propensity to be concentrated in urine.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Mayrer AR, Andriole VT<space/></arg><arg name="title">Urinary tract antiseptics<space/></arg><arg name="journal">Med. Clin. North Am.<space/></arg><arg name="volume">66<space/></arg><arg name="issue">1<space/></arg><arg name="pages">199–208<space/></arg><arg name="date">January 1982<space/></arg><arg name="pmid">7038329<space/></arg><arg name="doi"><space/></arg><arg name="url"></arg><arg name="last2">Andriole<space/></arg></template></extension><space/>In 1979, the publication of a patent<extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.google.com/patents/US4146719?dq</arg><arg name="title">Patent US4146719 - Piperazinyl derivatives of quinoline carboxylic acids - Google Patents<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>filed by the pharmaceutical arm of<space/><link><target>Kyorin Seiyaku Kabushiki Kaisha</target></link><space/>disclosed the discovery of<space/><link><target>norfloxacin</target></link>, and the demonstration that certain structural modifications including the attachment of a fluorine atom to the quinolone ring leads to dramatically enhanced antibacterial potency.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://aac.asm.org/content/21/5/848.full.pdf+<space/></arg><arg name="title">aac.asm.org<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>In the aftermath of this disclosure, several other pharmaceutical companies initiated research and development programs with the goal of discovering additional antibacterial agents of the fluoroquinolone class.</paragraph><paragraph>The fluoroquinolone program at<space/><link><target>Bayer</target></link><space/>focused on examining the effects of very minor changes to the norfloxacin structure.<extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.google.com/patents/US4547503?dq</arg><arg name="title">Patent US4547503 - 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-(oxo-alkyl)-1-piperazinyl ... - Google Patents<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.google.com/patents/US4544658?pg</arg><arg name="title">Patent US4544658 - 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(alkyl-1-piperazinyl)quinoline-3 ... - Google Patents<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>In 1983, the company published<space/><italics>in vitro</italics><space/>potency data for ciprofloxacin, a fluoroquinolone antibacterial having a chemical structure differing from that of norfloxacin by the presence of a single carbon atom.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Wise R, Andrews JM, Edwards LJ<space/></arg><arg name="title">In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents<space/></arg><arg name="journal">Antimicrob. Agents Chemother.<space/></arg><arg name="volume">23<space/></arg><arg name="issue">4<space/></arg><arg name="pages">559–64<space/></arg><arg name="date">April 1983<space/></arg><arg name="pmid">6222695<space/></arg><arg name="pmc">184701<space/></arg><arg name="doi"><space/>10.1128/aac.23.4.559</arg><arg name="url"></arg><arg name="last2">Andrews<space/></arg><arg name="last3">Edwards<space/></arg></template></extension><space/>This small change led to a two- to 10-fold increase in potency against most strains of Gram-negative bacteria. Importantly, this structural change led to a four-fold improvement in activity against the important<space/><link><target>Gram-negative</target></link><space/>pathogen<space/><italics><link><target>Pseudomonas aeruginosa</target></link></italics>, making ciprofloxacin one of the most potent known drugs for the treatment of this intrinsically antibiotic-resistant pathogen.<template><target>Medical citation needed</target><arg name="date">September 2015</arg></template></paragraph><paragraph>The oral tablet form of ciprofloxacin was approved in October 1987,<extension extension_name='ref'>http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=019537&amp;TABLE1=OB_Rx</extension><space/>just one year after the approval of norfloxacin.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No</arg><arg name="title">Orange Book Detail Record Search<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>In 1991, the intravenous formulation was introduced. Ciprofloxacin sales reached a peak of about 2 billion euros in 2001, representing 34% of Bayers total pharmaceutical revenues, before Bayer's patent expired in 2004, after which annual sales have averaged around 200 million.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.sec.gov/Archives/edgar/data/1144145/000115697302000306/f00360e20vf.txt<space/></arg><arg name="title">www.sec.gov<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><extension extension_name='ref'>Dan Prochilo for Law360 18 November 2013<space/><link type='external' href='http://www.law360.com/articles/489579/bayer-s-74m-cipro-pay-for-delay-deal-approved-in-calif'>Bayers $74M Cipro Pay-For-Delay Deal Approved In Calif.</link></extension></paragraph><heading level='2'>Society and culture</heading><heading level='3'>Cost</heading><paragraph>It is available as a generic medication and not very expensive.<extension extension_name='ref' name="AHFS2015"></extension><extension extension_name='ref' name="Ric2014"></extension><space/>Wholesale it costs between 0.03 and 0.13 USD a dose.<extension extension_name='ref' name="ERC2015"></extension><space/>In the United States it is sold for about 0.40 USD per dose.<extension extension_name='ref' name="AHFS2015"></extension></paragraph><heading level='3'>Generic equivalents</heading><paragraph>On 24 October 2001, the Prescription Access Litigation (PAL) project filed suit to dissolve an agreement between Bayer and three of its competitors which produced<space/><link><target>Generic drugs</target><part>generic versions of drugs</part></link><space/>(<link><target>Barr Pharmaceuticals</target><part>Barr Laboratories</part></link>,<space/><link><target>Actavis</target><part>Rugby Laboratories</part></link>, and<space/><link><target>Marion Merrell Dow</target><part>Hoechst-Marion-Roussel</part></link>) that PAL claimed was blocking access to adequate supplies and cheaper, generic versions of ciprofloxacin. The plaintiffs charged that Bayer Corporation, a unit of Bayer AG, had unlawfully paid the three competing companies a total of $200 million to prevent cheaper, generic versions of ciprofloxacin from being brought to the market, as well as manipulating its price and supply. Numerous other consumer advocacy groups joined the lawsuit. On 15 October 2008, five years after Bayer's patent had expired, the United States District Court for the Eastern District of New York granted Bayer's and the other defendants' motion for summary judgment, holding that any anticompetitive effects caused by the settlement agreements between Bayer and its codefendants were within the exclusionary zone of the patent and thus could not be redressed by federal antitrust law,<extension extension_name='ref'><template><target>cite web</target><arg name="author">United States Court of Appeals for the Federal Circuit<space/></arg><arg name="title">United States Court of Appeals for the Federal Circuit<space/></arg><arg name="url">http://www.cafc.uscourts.gov/opinions/08-1097.pdf<space/></arg><arg name="location">USA<space/></arg><arg name="format">PDF<space/></arg><arg name="year">2008<space/></arg><arg name="accessdate">4 September 2009<space/></arg><arg name="deadurl">yes<space/></arg><arg name="archiveurl">https://web.archive.org/20090827080527/http://www.cafc.uscourts.gov/opinions/08-1097.pdf<space/></arg><arg name="archivedate">27 August 2009<space/></arg></template></extension><space/>in effect upholding Bayer's agreement with its competitors.</paragraph><heading level='3'>Available forms</heading><paragraph>Ciprofloxacin for systemic administration is available as immediate-release tablets, as extended-release tablets, as an oral suspension, and as a solution for intravenous infusion. It is also available for local administration as eye drops and ear drops.</paragraph><heading level='3'>Litigation</heading><paragraph>A class action was filed against Bayer AG on behalf of employees of the Brentwood Post Office in Washington, D.C., and workers at the U.S. Capitol, along with employees of American Media, Inc. in Florida and postal workers in general who alleged they suffered serious adverse effects from taking ciprofloxacin (Cipro) in the aftermath of the<space/><link><target>2001 anthrax attacks</target><part>anthrax attacks in 2001</part></link>. The action alleged Bayer failed to warn class members of the potential side effects of the drug, thereby violating the Pennsylvania Unfair Trade Practices and Consumer Protection Laws. The class action was defeated and the litigation abandoned by the plaintiffs.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Legal Brief of Postal Employees Cases (EEOC, MSPB, District Courts)<space/></arg><arg name="url">http://www.lunewsviews.com/legal_briefs_archives.htm#cipro<space/></arg><arg name="archiveurl">http://web.archive.org/web/20071021073109/http://www.lunewsviews.com/legal_briefs_archives.htm#cipro<space/></arg><arg name="archivedate">21 October 2007<space/></arg><arg name="publisher">Postal Reporter<space/></arg><arg name="location">USA<space/></arg><arg name="accessdate">9 September 2009</arg></template></extension>A similar action was filed in 2003 in New Jersey by four New Jersey postal workers but was withdrawn for lack of grounds, as workers had been informed of the risks of cipro when they were given the option of taking the drug.<extension extension_name='ref'>Los Angeles Times, from wire service reports. October 19, 2003<space/><link type='external' href='http://articles.latimes.com/2003/oct/19/nation/na-briefs19.2'>Postal Workers Sue Over Anthrax Scare Antibiotic</link></extension><extension extension_name='ref'>Bill Lewis, President of Trenton Metro Area Local, American Postal Workers Union, AFL-CIO. December 7, 2003<space/><link type='external' href='http://trentonmetroarealocal.com/president_page.html'>Trenton Metro Area Local: Welcome to Bill's Corner</link><space/>Page accessed October 23, 2014</extension></paragraph><heading level='2'>References</heading><paragraph><template><target>reflist</target><arg name="colwidth">30em</arg></template></paragraph><heading level='2'>External links</heading><paragraph><template><target>Commons category</target></template><template><target>Portal</target><arg>Medical</arg></template></paragraph><list type='bullet'><listitem><template><target>DMOZ</target><arg>Society/Issues/Health/Drugs/Medical</arg></template></listitem><listitem><link type='external' href='http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Ciprofloxacin'>U.S. National Library of Medicine: Drug Information Portal - Ciprofloxacin</link></listitem><listitem><link type='external' href='http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s075,020780s033lbl.pdf'>Cipro Package Insert</link></listitem><listitem><link type='external' href='http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021744s008lbl.pdf'>Proquin XR Package Insert</link></listitem><listitem><link type='external' href='http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019992s020lbl.pdf'>Ciloxan Package Insert</link></listitem><listitem><link type='external' href='http://www.nlm.nih.gov/medlineplus/druginfo/meds/a605005.html'>Ciprofloxacin Ophthalmic</link></listitem><listitem><link type='external' href='http://www.antimicrobe.org/drugpopup/Ciprofloxacin.pdf'>Ciprofloxacin - Antimicrobe.org</link></listitem></list><paragraph><template><target>Clear</target></template><template><target>QuinoloneAntiBiotics</target></template><template><target>Piperazines</target></template><template><target>Otologicals</target></template><template><target>GABAergics</target></template></paragraph><paragraph><link><target>Category:Cyclopropanes</target></link><link><target>Category:Fluoroquinolone antibiotics</target></link><link><target>Category:Otologicals</target></link><link><target>Category:Ophthalmology drugs</target></link><link><target>Category:Piperazines</target></link><link><target>Category:GABAA receptor negative allosteric modulators</target></link><link><target>Category:RTT</target></link><link><target>Category:World Health Organization essential medicines</target></link></paragraph></article>